MAGEA8

Summary

MAGEA8 (MAGE family member A8, HGNC:6806) is a protein-coding gene on chromosome Xq28, encoding Melanoma-associated antigen 8 (P43361). Not known, though may play a role in embryonal development and tumor transformation or aspects of tumor progression.

This gene is a member of the MAGEA gene family. The members of this family encode proteins with 50 to 80% sequence identity to each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEA genes are clustered at chromosomal location Xq28. They have been implicated in some hereditary disorders, such as dyskeratosis congenita. Multiple alternatively spliced variants, encoding the same protein, have been identified.

Source: NCBI Gene 4107 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 42 total — 1 likely-pathogenic
• MANE Select transcript: NM_005364

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6806
Approved symbol	MAGEA8
Name	MAGE family member A8
Location	Xq28
Locus type	gene with protein product
Status	Approved
Aliases	MGC2182, CT1.8
Ensembl gene	ENSG00000156009
Ensembl biotype	protein_coding
OMIM	300341
Entrez	4107

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 3 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000286482, ENST00000345830, ENST00000493910, ENST00000535454, ENST00000542674

RefSeq mRNA: 3 — MANE Select: NM_005364 NM_001166400, NM_001166401, NM_005364

CCDS: CCDS14692

Canonical transcript exons

ENST00000286482 — 3 exons

Exon	Start	End
ENSE00001023874	149881183	149881285
ENSE00001023875	149884210	149885825
ENSE00001023876	149884073	149884134

Expression profiles

Bgee: expression breadth broad, 76 present calls, max score 82.60.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.1156 / max 33.9126, expressed in 31 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
197952	0.0867	28
197953	0.0289	14

Top tissues by expression

236 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
placenta	UBERON:0001987	82.60	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	65.68	gold quality
decidua	UBERON:0002450	58.82	gold quality
pancreatic ductal cell	CL:0002079	55.86	silver quality
ileal mucosa	UBERON:0000331	55.18	silver quality
right testis	UBERON:0004534	52.89	gold quality
hair follicle	UBERON:0002073	52.77	gold quality
mucosa of urinary bladder	UBERON:0001259	52.33	gold quality
left testis	UBERON:0004533	50.49	gold quality
epithelial cell of pancreas	CL:0000083	50.48	gold quality
frontal pole	UBERON:0002795	50.41	gold quality
middle frontal gyrus	UBERON:0002702	50.30	gold quality
testis	UBERON:0000473	50.21	gold quality
quadriceps femoris	UBERON:0001377	50.20	gold quality
paraflocculus	UBERON:0005351	50.18	gold quality
Brodmann (1909) area 10	UBERON:0013541	50.18	gold quality
metanephric glomerulus	UBERON:0004736	49.61	gold quality
thymus	UBERON:0002370	49.50	gold quality
oviduct epithelium	UBERON:0004804	49.50	gold quality
vastus lateralis	UBERON:0001379	49.45	gold quality
Brodmann (1909) area 46	UBERON:0006483	49.30	gold quality
cerebellar vermis	UBERON:0004720	49.25	gold quality
cervix squamous epithelium	UBERON:0006922	49.20	gold quality
olfactory bulb	UBERON:0002264	48.92	gold quality
myocardium	UBERON:0002349	48.87	gold quality
type B pancreatic cell	CL:0000169	48.83	gold quality
deltoid	UBERON:0001476	48.68	gold quality
mucosa of stomach	UBERON:0001199	48.56	gold quality
cardiac muscle of right atrium	UBERON:0003379	48.55	gold quality
CA1 field of hippocampus	UBERON:0003881	48.50	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.64

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

25 targeting MAGEA8, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-4496	99.88	68.89	2236
HSA-MIR-6516-3P	99.65	68.57	1238
HSA-MIR-142-3P	99.62	71.30	974
HSA-MIR-4261	99.59	70.30	3415
HSA-MIR-12123	99.52	71.79	2990
HSA-MIR-147B-5P	99.45	70.62	2432
HSA-MIR-6510-5P	99.14	66.59	1081
HSA-MIR-194-5P	99.01	69.65	1465
HSA-MIR-6761-5P	98.71	68.03	1504
HSA-MIR-4680-3P	98.64	68.60	2093
HSA-MIR-31-5P	98.58	68.35	1239
HSA-MIR-4773	98.35	67.30	1710
HSA-MIR-663B	97.40	62.91	664
HSA-MIR-4286	97.20	64.37	1587
HSA-MIR-6841-5P	97.19	67.29	409
HSA-MIR-215-3P	97.02	68.01	1209
HSA-MIR-1291	96.28	65.89	1224
HSA-MIR-759	96.16	66.77	873
HSA-MIR-6775-3P	95.76	65.91	982
HSA-MIR-550B-3P	95.43	67.73	599

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	ndnl2	ENSDARG00000058212
mus_musculus	Magea13	ENSMUSG00000046180
rattus_norvegicus	Magea13	ENSRNOG00000003532
drosophila_melanogaster	MAGE	FBGN0037481

Paralogs (37): MAGEC2 (ENSG00000046774), TRO (ENSG00000067445), MAGEB2 (ENSG00000099399), MAGED2 (ENSG00000102316), MAGEB4 (ENSG00000120289), MAGEA9 (ENSG00000123584), MAGEA10 (ENSG00000124260), MAGEA4 (ENSG00000147381), MAGED4 (ENSG00000154545), MAGEC1 (ENSG00000155495), MAGEC3 (ENSG00000165509), MAGEB6 (ENSG00000176746), MAGEB18 (ENSG00000176774), MAGEF1 (ENSG00000177383), MAGEB10 (ENSG00000177689), MAGED1 (ENSG00000179222), NDN (ENSG00000182636), MAGEB17 (ENSG00000182798), MAGEA2B (ENSG00000183305), NSMCE3 (ENSG00000185115), MAGEA11 (ENSG00000185247), MAGEE2 (ENSG00000186675), MAGED4B (ENSG00000187243), MAGEH1 (ENSG00000187601), MAGEB5 (ENSG00000188408), MAGEB16 (ENSG00000189023), MAGEA6 (ENSG00000197172), MAGEA1 (ENSG00000198681), MAGEB3 (ENSG00000198798), MAGEE1 (ENSG00000198934), MAGEA12 (ENSG00000213401), MAGEB1 (ENSG00000214107), MAGEA3 (ENSG00000221867), MAGEB6B (ENSG00000232030), MAGEL2 (ENSG00000254585), MAGEA9B (ENSG00000267978), MAGEA2 (ENSG00000268606)

Protein

Protein identifiers

Melanoma-associated antigen 8 — P43361 (reviewed: P43361)

Alternative names: Cancer/testis antigen 1.8, MAGE-8 antigen

All UniProt accessions (1): P43361

UniProt curated annotations — full annotation on UniProt →

Function. Not known, though may play a role in embryonal development and tumor transformation or aspects of tumor progression.

Tissue specificity. Expressed in many tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma and breast carcinoma, but not in normal tissues except for testis and placenta.

RefSeq proteins (3): NP_001159872, NP_001159873, NP_005355* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002190	MHD_dom	Domain
IPR021072	MAGE_N	Domain
IPR037445	MAGE	Family
IPR041898	MAGE_WH1	Homologous_superfamily
IPR041899	MAGE_WH2	Homologous_superfamily

Pfam: PF01454, PF12440

UniProt features (5 total): sequence variant 2, chain 1, domain 1, region of interest 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
8FJB	ELECTRON MICROSCOPY	3.06

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P43361-F1	75.72	0.49

Antibody-complex structures (SAbDab): 1 — 8FJB

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 60 (showing top): MORF_RAD51L3, MORF_CTSB, MORF_IL4, MORF_PRKCA, MORF_THPO, MORF_ATF2, SENESE_HDAC3_TARGETS_DN, MORF_PTPRR, GOMF_HISTONE_DEACETYLASE_BINDING, MORF_MAP2K7, MORF_IL16, MORF_DMPK, MORF_ERCC4, chrXq28, GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II

GO Biological Process (1): negative regulation of transcription by RNA polymerase II (GO:0000122)

GO Molecular Function (2): histone deacetylase binding (GO:0042826), protein binding (GO:0005515)

GO Cellular Component (1): nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
enzyme binding	1
binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

322 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MAGEA8	HSFX4	A0A1B0GTS1	506
MAGEA8	EOLA2	Q96DE9	402
MAGEA8	CXorf51A	A0A1B0GTR3	399
MAGEA8	XAGE1B	Q9HD64	380
MAGEA8	FMR1NB	Q8N0W7	368
MAGEA8	SPANXD	Q9BXN6	366
MAGEA8	FATE1	Q969F0	351
MAGEA8	FTHL17	Q9BXU8	351
MAGEA8	SPANXN4	Q5MJ08	348
MAGEA8	SPANXN3	Q5MJ09	325
MAGEA8	CTAG1A	P78358	323
MAGEA8	OR7D2	Q96RA2	313
MAGEA8	EOLA1	Q8TE69	310
MAGEA8	SPANXN2	Q5MJ10	309
MAGEA8	GAGE2A	Q6NT46	308

IntAct

76 interactions, top by confidence:

A	B	Type	Score
MAGEA8	GCA	psi-mi:“MI:0915”(physical association)	0.830
GCA	MAGEA8	psi-mi:“MI:0915”(physical association)	0.830
MLH1	MAGEA8	psi-mi:“MI:0915”(physical association)	0.780
MAGEA8	MLH1	psi-mi:“MI:0915”(physical association)	0.780
BEX5	MAGEA8	psi-mi:“MI:0915”(physical association)	0.760
MAGEA8	BEX5	psi-mi:“MI:0915”(physical association)	0.760
MAGEA8	PKD2	psi-mi:“MI:0915”(physical association)	0.670
PKD2	MAGEA8	psi-mi:“MI:0915”(physical association)	0.670
EFNB3	DENND11	psi-mi:“MI:0914”(association)	0.640
MAGEA8	MAGEB4	psi-mi:“MI:0915”(physical association)	0.560
MAGEA8	LMO2	psi-mi:“MI:0915”(physical association)	0.560
MAGEA8	MTUS2	psi-mi:“MI:0915”(physical association)	0.560
LXN	MAGEA8	psi-mi:“MI:0915”(physical association)	0.560
LMO2	MAGEA8	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (154): MAGEA8 (Two-hybrid), MAGEB4 (Two-hybrid), PKD2 (Two-hybrid), MTUS2 (Two-hybrid), GCA (Two-hybrid), LXN (Two-hybrid), BEX5 (Two-hybrid), MAGEA8 (Two-hybrid), MAGEA8 (Two-hybrid), MAGEA8 (Two-hybrid), MAGEA8 (Two-hybrid), MAGEA8 (Two-hybrid), GCA (Two-hybrid), BEX5 (Two-hybrid), MAGEA8 (Two-hybrid)

ESM2 similar proteins: A0A0G2JMD5, A0A0J9YX57, A2A368, A2A9R3, A6NCF6, A6NK02, A8MXT2, D9I2F9, D9I2G3, D9I2H0, O15479, O15480, O15481, O60809, O95521, P14373, P25233, P43355, P43356, P43357, P43358, P43360, P43361, P43362, P43363, P43364, P43365, P43366, Q2LKU9, Q2LKW6, Q4R998, Q5PPP4, Q5SWL7, Q62191, Q6AY37, Q6AZZ1, Q8BQR7, Q8BVP1, Q8K243, Q8N7X4

Diamond homologs: A0A0J9YX57, A1A5P9, A2A368, A2A9R3, A6NCF6, A6QLI5, A8MXT2, O15479, O15480, O15481, O60732, P25233, P43355, P43356, P43357, P43358, P43360, P43361, P43362, P43363, P43364, P43365, P43366, Q12816, Q4R998, Q5PPP4, Q5RFC2, Q6AY37, Q6ITT4, Q6PCZ4, Q8BQR7, Q8N7X4, Q8TD90, Q8TD91, Q96JG8, Q96LZ2, Q96M61, Q96MG7, Q99608, Q9BE18

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

42 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	36
Likely benign	5
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
694602	GRCh37/hg19 Xq28(chrX:148882560-149686856)x2	Likely pathogenic

SpliceAI

445 predictions. Top by Δscore:

Variant	Effect	Δscore
X:149884130:GACCT:G	donor_gain	1.0000
X:149884131:ACCT:A	donor_gain	1.0000
X:149884132:CCT:C	donor_gain	1.0000
X:149884135:G:GG	donor_gain	1.0000
X:149881255:G:T	donor_gain	0.9900
X:149884068:TTCA:T	acceptor_loss	0.9900
X:149884069:TCAG:T	acceptor_loss	0.9900
X:149884070:CAG:C	acceptor_loss	0.9900
X:149884071:A:AG	acceptor_gain	0.9900
X:149884072:G:GA	acceptor_loss	0.9900
X:149884072:G:GG	acceptor_gain	0.9900
X:149884131:ACCTG:A	donor_loss	0.9900
X:149884132:CCTG:C	donor_loss	0.9900
X:149884133:CT:C	donor_gain	0.9900
X:149884134:TG:T	donor_loss	0.9900
X:149884135:G:GA	donor_loss	0.9900
X:149884136:TA:T	donor_loss	0.9900
X:149884137:AAGTA:A	donor_loss	0.9900
X:149884138:AGTAG:A	donor_loss	0.9900
X:149884209:GGCCT:G	acceptor_gain	0.9900
X:149881255:G:GT	donor_gain	0.9800
X:149884139:G:C	donor_loss	0.9800
X:149884205:CCCA:C	acceptor_loss	0.9700
X:149884206:CCA:C	acceptor_loss	0.9700
X:149884207:CA:C	acceptor_loss	0.9700
X:149884208:A:AG	acceptor_gain	0.9700
X:149884208:AGGC:A	acceptor_loss	0.9700
X:149884209:G:GG	acceptor_gain	0.9700
X:149884071:AG:A	acceptor_gain	0.9600
X:149884072:GG:G	acceptor_gain	0.9600

AlphaMissense

2081 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:149884765:T:C	F165L	0.951
X:149884767:T:A	F165L	0.951
X:149884767:T:G	F165L	0.951
X:149885092:T:C	F274L	0.942
X:149885094:C:A	F274L	0.942
X:149885094:C:G	F274L	0.942
X:149885093:T:C	F274S	0.932
X:149884720:T:C	F150L	0.928
X:149884722:T:A	F150L	0.928
X:149884722:T:G	F150L	0.928
X:149885029:T:A	W253R	0.911
X:149885029:T:C	W253R	0.911
X:149885098:T:A	W276R	0.907
X:149885098:T:C	W276R	0.907
X:149885101:G:C	G277R	0.881
X:149884685:T:C	M138T	0.878
X:149884769:G:T	G166V	0.869
X:149884685:T:G	M138R	0.859
X:149884651:T:G	Y127D	0.858
X:149884721:T:G	F150C	0.857
X:149885100:G:C	W276C	0.856
X:149885100:G:T	W276C	0.856
X:149884741:G:C	A157P	0.851
X:149884955:T:C	L228S	0.850
X:149884652:A:C	Y127S	0.849
X:149884650:A:C	K126N	0.845
X:149884650:A:T	K126N	0.845
X:149885093:T:G	F274C	0.845
X:149884895:T:A	V208D	0.840
X:149885031:G:C	W253C	0.833

dbSNP variants (sampled 300 via entrez): RS1000910998 (X:149880735 G>A), RS1001364874 (X:149881158 G>A), RS1003477493 (X:149883353 G>A), RS1003828145 (X:149883072 A>T), RS1004370102 (X:149881639 G>A), RS1005424739 (X:149883798 A>G), RS1007321754 (X:149882889 T>G), RS1007397213 (X:149884732 T>C), RS1007678094 (X:149882445 G>A,T), RS1009172971 (X:149883019 C>T), RS1011522704 (X:149884791 C>G), RS1013521956 (X:149881197 G>A), RS1013546862 (X:149885753 C>A,G), RS1015775931 (X:149881915 G>T), RS1016439013 (X:149885779 T>C)

Disease associations

OMIM: gene MIM:300341 | disease phenotypes: MIM:252350

GenCC curated gene-disease

Mondo (1): Moyamoya disease (MONDO:0016820)

Orphanet (1): Moyamoya disease (Orphanet:2573)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D009072	Moyamoya Disease	C10.228.140.300.200.600; C10.228.140.300.510.200.737; C14.907.137.615; C14.907.253.123.620; C14.907.253.560.200.737

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

12 total (human), top 12 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Tamoxifen	affects expression, affects cotreatment, decreases expression	2
Raloxifene Hydrochloride	affects expression, affects cotreatment, decreases expression	2
perfluorooctanoic acid	increases expression	1
perfluorooctane sulfonic acid	increases expression	1
CGP 52608	affects binding, increases reaction	1
perfluoro-n-nonanoic acid	increases expression	1
perfluorohexanesulfonic acid	increases expression	1
Resveratrol	decreases expression, affects cotreatment	1
Decitabine	increases expression	1
Benzo(a)pyrene	affects methylation, decreases methylation	1
Diethylhexyl Phthalate	decreases expression	1
Plant Extracts	affects cotreatment, decreases expression	1

Clinical trials (associated diseases)

45 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04205578	PHASE3	UNKNOWN	NBP in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events
NCT07065409	PHASE1	RECRUITING	Treatment of Moyamoya Disease With iPSC-derived Exosomes
NCT07286110	PHASE1	NOT_YET_RECRUITING	Chinese Herbal Therapy (Qiqi Shengmai Formula) for Moyamoya Vasculopathy: The CHIMES Trial
NCT03162588	PHASE1/PHASE2	COMPLETED	Multiple Burrhole Therapy With Erythropoietin for Unstable Moyamoya
NCT01419275	Not specified	COMPLETED	Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya Disease and Stroke Patients
NCT01793168	Not specified	RECRUITING	Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
NCT02074111	Not specified	UNKNOWN	Moyamoya Disease Biomarkers in Patients With Intracranial Atherosclerotic Stroke
NCT02305407	Not specified	UNKNOWN	Neurocognitive and Radiological Assessments in Adult Moyamoya Undergoing Surgery
NCT02510586	Not specified	UNKNOWN	Sevoflurane and Hyperperfusion Syndrome
NCT02982135	Not specified	UNKNOWN	Direct Bypass Versus Indirect Bypass in Treatment of Adults Hemorrhagic Moyamoya Disease
NCT03072914	Not specified	COMPLETED	Effects of Remote Ischemic Preconditioning With Postconditioning on Neurologic Outcome
NCT03516851	Not specified	WITHDRAWN	Precision Bypass in Patients With Moyamoya Disease
NCT03543748	Not specified	UNKNOWN	Efficacy and Safety of rTMS for Cognitive Rehabilitation in Moyamoya Disease
NCT03546309	Not specified	RECRUITING	Safety and Efficacy of RIC in Pediatric Moyamoya Disease Patients Treated With Revascularization Therapy
NCT03613701	Not specified	UNKNOWN	Relationship Between Endothelial Progenitor Cells and Revascularization Effect of Moyamoya Disease
NCT03627975	Not specified	UNKNOWN	Effect of Surgical Revascularization on Hemorrhagic Moyamoya Disease
NCT03785171	Not specified	UNKNOWN	Predicative Value of Multimodal MRI in Moyamoya Disease
NCT03821181	Not specified	UNKNOWN	The Effect of RIC on TIA/Stroke in Children With Moyamoya Disease
NCT03882060	Not specified	UNKNOWN	Effect of Recombinant Human EPO on the Postoperative Neurologic Outcome in Pediatric Moyamoya Patients
NCT04012268	Not specified	COMPLETED	The Safety and Efficacy of RIC on Adult Moyamoya Disease
NCT04064658	Not specified	SUSPENDED	Effects of Remote Ischemic Pre-Conditioning in Moyamoya Disease Patients
NCT04696094	Not specified	UNKNOWN	The Role of m6A RNA Modification in Moyamoya Disease
NCT04890782	Not specified	UNKNOWN	Gut Microbiota in Patients With Moyamoya Disease
NCT04906564	Not specified	COMPLETED	RNF213 Variants and Collateral Vessels in Moyamoya Disease
NCT04917003	Not specified	UNKNOWN	Safety and Efficacy of Remote Ischemic Conditioning Combined EDAS on Ischemic Moyamoya Disease
NCT05332756	Not specified	RECRUITING	Long-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives (LAMORA)
NCT05491980	Not specified	ACTIVE_NOT_RECRUITING	Florida Cerebrovascular Disease Biorepository and Genomics Center
NCT05619068	Not specified	RECRUITING	The Evolution and Prognosis of Moyamoya Disease
NCT05772572	Not specified	COMPLETED	Functional Disorders Moya Moya Young Patients
NCT05860946	Not specified	UNKNOWN	Remote Ischemic Conditioning in Adult Moyamoya Disease Patients
NCT05961748	Not specified	RECRUITING	Registry of Multicenter Brain-Heart Comorbidity in China
NCT06041659	Not specified	RECRUITING	Functional Magnetic Resonance-Based Observations of Brain Networks in Moyamoya Disease Patients Under Anesthesia
NCT06051552	Not specified	NOT_YET_RECRUITING	Prognostic Prediction Model in Patients With Moyamoya Disease Undergoing Revascularization Surgery
NCT06330818	Not specified	RECRUITING	Imaging in Moyamoya Disease - Study to Investigate Different Imaging Technologies for a Better Understanding of Various Imaging Techniques to Evaluate Cerebral Hemodynamics, Disease-activity and Possibly the Etiology in Moyamoya Patients
NCT06477107	Not specified	ENROLLING_BY_INVITATION	A Study of Cerebral Perfusion With tDCS in Chronic Hypoperfusion
NCT06634004	Not specified	ENROLLING_BY_INVITATION	Biomarker-Led Optimization of Successful Surgical Outcomes in Moyamoya
NCT06714097	Not specified	RECRUITING	Application of Digital Twins’ Technology in Patients Who Had a Stroke, With Moyamoya Disease and With Cerebral Amyloid Angiopathy (CAA) During the Secondary Prevention Phase: A Proof of Concept Using a Randomized Control Trial (Clinical Study 6, STRATIF-AI Project)
NCT06724029	Not specified	RECRUITING	Neurosurgical Outcome Network
NCT06817434	Not specified	RECRUITING	Study on Evaluating the Effectiveness of Statins in the Treatment of Moyamoya Disease
NCT06832839	Not specified	RECRUITING	Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease